Last reviewed · How we verify
NCT06744647: CONCORD
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Phase 2 trial testing ALXN2030 in Antibody-Mediated Rejection in 45 participants. Currently enrolling.
11 October 2027
Quick facts
| Lead sponsor | Alexion Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 7 March 2025 |
| Primary completion | 11 October 2027 |
| Estimated completion | 7 November 2028 |
| Sites | 55 locations across Taiwan, United Kingdom, South Korea, Canada, China, Spain, United States, Brazil |
Drugs / interventions tested
- ALXN2030 — full drug profile →
- Placebo
Conditions studied
- Antibody-Mediated Rejection — all drugs for Antibody-Mediated Rejection →
- Kidney Transplantation — all drugs for Kidney Transplantation →
- Biopsy-proven Histologic Scores — all drugs for Biopsy-proven Histologic Scores →
- AMR — all drugs for AMR →
Sponsor
Alexion Pharmaceuticals, Inc. — full company profile →
Who can join
Adults 18 to 75, any sex, with Antibody-Mediated Rejection or Kidney Transplantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06744647
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ALXN2030
Trials testing the same drug.
- NCT05501717 — Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants · Phase 1 · active not recruiting
Other recruiting trials for Antibody-Mediated Rejection
Currently open trials in the same condition.
- NCT07316829 — TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Re · active not recruiting
Other Alexion Pharmaceuticals, Inc. trials
Trials by the same sponsor.
- NCT06015750 — Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia · Phase 4 · withdrawn
- NCT07352423 — Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants · Phase 1 · recruiting
- NCT07221838 — A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab · Phase 4 · recruiting
- NCT07413250 — Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis o · active not recruiting
- NCT07308574 — Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06744647 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alexion Pharmaceuticals, Inc.
- Last refreshed: 1 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06744647.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing